People · Operator
Named in public records as an officer, director or promoter · active 2014–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alpine Immune Sciences, Inc. | — | Biotechnology | Series C | $234.9M | $2.3B | 2014 |
| Scipher Medicine Corp | — | Biotechnology | Series C | $123.0M | $55.5M | 2018 |
| Leap Therapeutics, Inc. | — | Pharmaceuticals | Series C | $105.1M | $1.1B | 2017 |
Joseph Loscalzo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joseph Loscalzo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Samir Kaul | 1 | 32 |
| David Miller | 1 | 29 |
| John Moore | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| Michael Rubin | 1 | 8 |
| Augustine Lawlor | 1 | 8 |
| Augustine E. Lawlor | 1 | 6 |
| Christopher Mirabelli | 1 | 6 |
| Jay Venkatesan | 1 | 5 |
| Douglas E. Onsi | 1 | 5 |
| Todd Sone | 1 | 4 |
| Christopher K. Mirabelli | 1 | 4 |
| Thomas Dietz | 1 | 4 |
| Douglas Onsi | 1 | 3 |
| William Li | 1 | 3 |
| James Paul Rickey | 1 | 3 |
| TIM ANDERSON | 1 | 3 |
| Miklos Kobor | 1 | 3 |
| Evan Loh | 1 | 2 |
| Howard Furst | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.